Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Age-associated memory impairment: a role for catecholamines.

W J McEntee1, T H Crook

  • 1Memory Assessment Clinics Inc., Sarasota, FL 34239.

Neurology
|March 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neuropeptide dietary supplement N-PEP-12 enhances cognitive function and activates brain bioelectrical activity in healthy elderly subjects.

Methods and findings in experimental and clinical pharmacology·2005
Same author

Raloxifene hydrochloride, a selective estrogen receptor modulator: safety assessment of effects on cognitive function and mood in postmenopausal women.

Psychoneuroendocrinology·1999
Same author

Wernicke's encephalopathy: an excitotoxicity hypothesis.

Metabolic brain disease·1997
Same author

Nicergoline: parallel evolution of clinical trial methodology and drug development in dementias.

Dementia and geriatric cognitive disorders·1997
Same author

Age-associated memory impairment: sorting out the controversies.

Neurology·1995
Same author

Structure of everyday memory in adults with Age-Associated Memory Impairment.

Psychology and aging·1994
Same journal

Factors Associated With Disability Improvement and Worsening Independent of Attacks in Patients With AQP4-IgG+ NMOSD and MOGAD: A Multicenter Cohort Study.

Neurology·2026
Same journal

Cost-Effectiveness of Intracranial Aneurysm Screening: A Systematic Review.

Neurology·2026
Same journal

Rare Eating Epilepsy: Co-Occurrence of Focal Cortical Dysplasia and Gray Matter Heterotopia.

Neurology·2026
Same journal

Spatiotemporal Associations Between Cortical Microinfarcts and Cortical Superficial Siderosis in Cerebral Amyloid Angiopathy.

Neurology·2026
Same journal

Blood-Brain Barrier Disruption Before Interhospital Transfer for Thrombectomy and Clinical Outcome.

Neurology·2026
Same journal

At Death's Door: Cytosolic Dopamine in Patients With Parkinson Disease.

Neurology·2026
See all related articles

Age-associated memory impairment (AAMI) affects healthy individuals over 50. This review explores the role of catecholamines, beyond acetylcholine, in AAMI and suggests potential therapeutic strategies.

Area of Science:

  • Neuroscience
  • Gerontology
  • Pharmacology

Background:

  • Age-associated memory impairment (AAMI) is a common cognitive decline in healthy individuals over 50.
  • Current research on AAMI primarily focuses on cholinergic systems, neglecting other neurochemical pathways.
  • Diminished catecholamine function is linked to age-related dementias and may also impact AAMI.

Purpose of the Study:

  • To propose a significant role for catecholamines in the neurochemical basis of AAMI.
  • To explore potential therapeutic strategies targeting catecholamine systems for AAMI treatment.
  • To shift research focus towards catecholamines in understanding and treating age-related memory loss.

Main Methods:

  • Review of existing literature on AAMI and neurochemical systems.

Related Experiment Videos

  • Analysis of studies implicating catecholamines in cognitive function and aging.
  • Synthesis of evidence to support a catecholaminergic hypothesis for AAMI.

    • Main Results:

    • Evidence suggests catecholamine dysfunction contributes to age-associated memory impairment.
    • Cholinergic focus in AAMI research may overlook crucial neurochemical mechanisms.
    • Catecholamine pathways represent a promising target for novel AAMI treatments.

    Conclusions:

    • Catecholamines are likely involved in the pathophysiology of AAMI.
    • Targeting catecholamine systems offers a potential avenue for therapeutic intervention in AAMI.
    • Further research into catecholaminergic mechanisms is warranted for effective AAMI management.